Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)
ConclusionResults provide continued support for the use of multiple monthly administrations of SEL-037 0.2 mg/kg + SEL-110 0.1-0.15 mg/kg in clinical trials for SEL-212.Trial RegistrationClinicalTrials.gov identifier, NCT02959918. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - April 17, 2023 Category: Rheumatology Source Type: research
A Narrative Review of Acthar Gel for the Treatment of Myositis
AbstractIdiopathic inflammatory myopathies (IIMs) are autoimmune disorders characterized by symmetric proximal muscle weakness and chronic inflammation, with an increased risk of morbidity and mortality. The current standard of care includes traditional immunosuppressive pharmacotherapies; however, some patients cannot tolerate or do not adequately respond to these therapies, highlighting the need for alternative treatments for refractory disease. Acthar® Gel (repository corticotropin injection) is a naturally sourced mixture of adrenocorticotropic hormone analogs and other pituitary peptides that has been approved by the...
Source: Rheumatology and Therapy - March 26, 2023 Category: Rheumatology Source Type: research
Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study
ConclusionsNon-inferior efficacy of CMAB008 to innovator infliximab is illustrated with similar early and lasting therapeutic effects, and the equivalence is further demonstrated. CMAB008 is well tolerated and has semblable safety compared with the innovator infliximab.Trial registration numberNCT03478111. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 25, 2023 Category: Rheumatology Source Type: research
Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
ConclusionsIn this real-world study, the risk of hospitalization and PAH disease progression were similar between the two cohorts who received oral selexipag. The results from this study corroborate findings of the GRIPHON post hoc analysis of PAH-associated CTD patients and support oral selexipag use in PAH-CTD patients. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 23, 2023 Category: Rheumatology Source Type: research
Clinical Presentation and Treatment of Juvenile Idiopathic Arthritis Combined with Lung Disease: A Narrative Review
AbstractJuvenile idiopathic Arthritis (JIA) is a common rheumatic disorder in children that can cause multiple systems to be affected simultaneously, leading to severe clinical symptoms and a high mortality rate in those with pulmonary involvement. Pleurisy is the most common manifestation of pulmonary involvement. At the same time, other conditions, such as pneumonia, interstitial lung disease, occlusive bronchiectasis, and alveolar protein deposition, have been increasingly reported in recent years. This review aims to provide an overview of the clinical manifestations of JIA lung damage and the current treatment options...
Source: Rheumatology and Therapy - March 11, 2023 Category: Rheumatology Source Type: research
Patients with Axial Spondyloarthritis are Great Consumers of Healthcare Resources, Especially Young and Women: Results from the Spanish Atlas
ConclusionHalf of patients with axSpA used 25 or more healthcare resources during 1 year. Higher healthcare utilization was associated with younger age, female gender, greater disease activity, higher functional limitation and longer diagnostic delay. Optimal monitoring of patients with axSpA may help to reduce their healthcare utilization. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 6, 2023 Category: Rheumatology Source Type: research
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
ConclusionsThe stringent primary endpoint was not met. However, in patients achieving sustained SDAI remission, numerically more maintained remission with continued abatacept + methotrexate versus abatacept monotherapy or withdrawal.Trial RegistrationClinicalTrials.gov identifier, NCT02504268.Video abstract (MP4 62241 KB) (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 3, 2023 Category: Rheumatology Source Type: research
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
ConclusionsCZP durability was comparable with durability data on other bDMARDs in RA patients. Patient characteristics that were associated with greater durability included younger age, TNFi-na ïvety, and disease duration ≥ 1 year. Findings may be helpful in informing clinicians on a patient’s likelihood of discontinuing CZP, based on their baseline characteristics. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 27, 2023 Category: Rheumatology Source Type: research
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
ConclusionsRA patients treated with IV golimumab or infliximab achieved comparable improvements across social, mental, and physical well-being PROMIS measures. Additionally, PROMIS detected meaningful clinical changes in patient-reported outcomes in both treatment groups.ClinicalTrials.gov registration numberNCT02728934. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 23, 2023 Category: Rheumatology Source Type: research
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis
ConclusionsUpadacitinib 15 mg demonstrated rapid and clinically meaningful improvements in disease activity, pain, FACIT-F, function, HRQoL, and WPAI among bDMARD-IR patients with active AS.Trial RegistryClinical Registration number: NCT04169373, SELECT-AXIS 2. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 23, 2023 Category: Rheumatology Source Type: research
Immune Thrombocytopenia Could be an Independent Clinical Phenotype of Antiphospholipid Syndrome: A Prospective Cohort Study
ConclusionsIn the absence of other high-risk factors for thrombosis, thrombocytopenia could be an independent and long-lasting clinical phenotype of APS. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 20, 2023 Category: Rheumatology Source Type: research
A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan
ConclusionThis study presents the long-term real-world results for persistence of GLM and its potential determinants. These most recent and long-term observations demonstrated that GLM and other bDMARDs continue to benefit patients with RA in Japan. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 18, 2023 Category: Rheumatology Source Type: research
Clinical Characteristics of Dermatomyositis with Interstitial Lung Disease: A Retrospective Case –Control Study
ConclusionsDM patients with ILD usually present with older age, higher rates of CADM, Gottron's papules, mechanic ’s hands, myocardial involvement, higher positive rates of anti-MDA5 and anti-SSA/Ro52 antibodies, lower ALB, PNI, and lower rates of muscle weakness and heliotrope rash. Old age, Gottron’s papules, and anti-SSA/Ro52 were independent risk factors for ILD in DM. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 18, 2023 Category: Rheumatology Source Type: research
Patient Experience of Sj ögren’s Disease and its Multifaceted Impact on Patients’ Lives
ConclusionThe results of this SML study show that Sj ögren's affects diverse aspects of patients’ lives, with symptoms extending beyond dry eyes and mouth and impacting daily living and functioning. Because symptoms may affect patients differently, these results highlight the importance of measuring impact on HRQoL to assess patient outcomes and tr eatment options in routine clinical practice and clinical trials. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 16, 2023 Category: Rheumatology Source Type: research
Psoriatic Arthritis in Males and Females: Differences and Similarities
ConclusionsPsoriasis is more present in males, but it seems to be related to a worse impact in females. In particular, a possible role of psoriasis as an influencing factor the PtGA was found. Moreover, female PsA patients tended to have more disease activity, worse function, and higher disease burden. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 16, 2023 Category: Rheumatology Source Type: research
